A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess how selpercatinib gets into the blood stream and
how long it takes the body to remove it when administered to participants with impaired
hepatic function compared to healthy participants. Information about safety and tolerability
will be collected. The study will last up to about 7 weeks, inclusive of screening period.